Mads Krogsgaard Thomsen joined Novo Nordisk in 1991 as head of Growth Hormone Research. He was appointed senior vice president of Diabetes R&D in 1994 and in November 2000 he was appointed executive vice president and chief science officer.?In this role, he is responsible for global drug and device research, CMC and global development, medical affairs, regulatory and safety within Novo Nordisk.
Professor Thomsen has chaired Danish Research Council programmes within endocrinology, and has served as president of the National Academy of Technical Sciences (ATV), Denmark. Today, he serves as chair of the board of the University of Copenhagen, Denmark, and as member of the board of Symphogen A/S, Denmark. He is also a member of the editorial boards of international, peer-reviewed journals.
Professor Thomsen has a DVM from the Royal Veterinary and Agricultural University (now the Faculty of Health and Medical Sciences of the University of Copenhagen), Denmark, from 1986, where he also obtained a PhD in 1989 and a DSc in 1991, and has served as adjunct professor of pharmacology since 2000.
Professor Thomsen is a Danish national, born December 1960.